PERISCOPE annual meeting 2017 in Prague
From March 8-10 the PERISCOPE Consortium came together for its annual meeting in Prague (Czech Republic), the hometown of the project partner Institute of Microbiology of the ASCR, v. v. i. (IMIC), to discuss the project’s progress and future collaboration.
The meeting was arranged as a three day event, combining a stakeholder session on March 8 with two full consortia meeting days on March 9 and 10, 2017. All meeting participants were committed to share what has been achieved during the first year of the project and to structure the tasks ahead.
A great opportunity to share lessons learned and network
In the course of the stakeholder session, the consortium had the chance to meet with invited representatives of the related IMI projects Biovacsafe (represented by the EFPIA coordinator of Biovacsafe Giuseppe Del Giudice, GSK Vaccines), Advance (represented by the EFPIA coordinator of Advance Vincent Bauchau, GSK Vaccines) and SAFE-T (represented by the coordinator of SAFE-T Michael Merz, Novartis, and his colleague Nicole Schneiderhan-Marra, NMI Natural and Medical Sciences Institute at the University of Tübingen) to discuss potential interactions between PERISCOPE and the invited consortia and to share lessons learned.
The programme of the annual meeting provided each partner with the opportunity to address the progress and challenges within the different work packages of the project, including updates and outlooks on research, dissemination and management activities. The final meeting day provided time for several topic specific breakout sessions, where current challenges and those ahead were discussed in parallel by smaller working groups. The afternoon was dedicated to clinical studies and related data and sample management tasks within PERISCOPE. Here, members of the clinical study teams were discussing the clinical study protocols and the supporting technical as well as logistical activities needed for a successful implementation and coherence of the studies.
The next meeting will take place in March 2018 in Lyon, France.
PERISCOPE is a 5-year collaborative project funded by the Innovative Medicines Initiative 2, a Joint Undertaking receiving support from the European Union’s Horizon 2020 research and innovation programme, the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Bill & Melinda Gates Foundation. It aims to accelerate the development of improved vaccines against Bordetella pertussis (whooping cough) and vaccination strategies that will be used to control Bordetella pertussis in humans. For more information visit the PERISCOPE website.
Eurice is involved in PERISCOPE as the management partner and contributes to the successful implementation of the project goals.
Tags: Horizon 2020